Дана Юнусовна Намитокова

Dr. Дана Юнусовна Намитокова

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in Ateroscleroz
Verified
Journal Article
Open access
PDF file
Alim NamitokovAlim Namitokov
Alim Namitokov
IGI. V. Gilevich
I. V. Gilevich
NIN. S. Iraklionova
N. S. Iraklionova
ДНДана Юнусовна Намитокова
Дана Юнусовна Намитокова
Objective – to assess circulating sortilin levels in patients with early clinically significant coronary atherosclerosis and to investigate associations between sortilin, composite cell-based inflammatory indices, and standard lipid parameters. Material and Methods. A case–control study was conducted at the Scientific Research Institution–Regional Clinical Hospital No. 1 named after Prof. S.V. Ochapovsky (Krasnodar, Russia) from January to June 2023. The clinical group comprised patients hospitalized with non-ST-segment elevation acute coronary syndrome without myocardial infarction (unstable angina) and angiographically confirmed clinically significant coronary atherosclerosis (≥ 50 % stenosis in at least one segment). The control group (individuals without atherosclerosis) was selected using a «random envelope» method. Sortilin was measured by ELISA (Aviscera Bioscience, USA). Systemic inflammatory indices (SII, SIRI, AISI, NLR, PLR, MLR), fibrinogen, and lipid profile were assessed. Data are presented as median (Q1; Q3). Between-group comparisons used the Mann–Whitney U test; correlations were evaluated using Spearman’s rho. Results. A total of 128 participants were analyzed: 101 patients with clinically significant atherosclerosis and 27 controls. Sortilin levels were higher in the atherosclerosis group: 8.6 (2.6; 17.1) vs 2.3 (1.25; 10.65), p = 0.0058. Sortilin showed positive correlations with SII (ρ = 0.218, p = 0.013), SIRI (ρ = 0.203, p = 0.022), AISI (ρ = 0.210, p = 0.017), and NLR (ρ = 0.200, p = 0.023). No significant correlations were found between sortilin and PLR, MLR, fibrinogen, or standard lipid parameters (TC, LDL-C, HDL-C, triglycerides). Conclusions. Circulating sortilin is elevated in patients with early clinically significant coronary atherosclerosis and is associated with cell-based composite inflammatory indices, while showing no association with the standard lipid profile. These findings support sortilin as a potential marker of early atherosclerosis reflecting predominantly inflammatory–immune pathways.

27 March 2026 in South Russian Journal of Therapeutic Practice
Verified
Journal Article
Open access
PDF file
Alim NamitokovAlim Namitokov
Alim Namitokov
EDE. Ye. Dmitrieva
E. Ye. Dmitrieva
ДНДана Юнусовна Намитокова
Дана Юнусовна Намитокова
VDV. E. Dzhodzhua
V. E. Dzhodzhua
ASA. S. Shimko
A. S. Shimko
VKV. V. Korchagin
V. V. Korchagin
This systematic review aimed to evaluate long-term outcomes after CABG in patients with FH and to identify major determinants of prognosis. A systematic literature search was performed in PubMed/MEDLINE, Embase, Web of Science, and the Cochrane Library following PRISMA guidelines. Among 139 identified records, 17 studies met inclusion criteria and provided data on surgical revascularization in heterozygous and homozygous FH. Historical cohorts (Takahashi, Kawasuji and colleagues) demonstrated that the use of internal thoracic artery grafts combined with aggressive lipid lowering—including LDL apheresis—provides 10–18-year survival rates of 80–90%, with most late adverse events related to vein-graft atherosclerosis. Contemporary registries (Béliard, Iyen, HELLAS-FH) indicate that failure to achieve LDL-C targets substantially increases residual cardiovascular risk, while diabetes and socioeconomic deprivation further worsen outcomes. Modern CABG cohorts (Deconinck et al.) show that FH is associated with more than a twofold increase in MACE risk when preoperative lipid control is suboptimal. Long-term CABG outcomes in FH can be favorable when arterial conduits are used and strict LDL-C targets are achieved. Prognosis is driven not only by coronary anatomy but also by the quality of secondary prevention, accessibility of lipid-lowering therapy, and comorbid conditions. Further research is needed in the contemporary era of PCSK9 inhibitors and lipoprotein apheresis.

25 March 2026 in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
Alim NamitokovAlim Namitokov
Alim Namitokov
IGIrina Gilevich
Irina Gilevich
OMOlga Malyarevskaya
Olga Malyarevskaya
NINatalia Iraklionova
Natalia Iraklionova
КККарина Карабахциева
Карина Карабахциева
ДНДана Юнусовна Намитокова
Дана Юнусовна Намитокова
Background: Sortilin (SORT1), linked to the 1p13.3 coronary risk locus, is implicated in lipid trafficking and atherogenesis; however, clinical studies of circulating SORT1 have produced inconsistent results. We evaluated whether circulating SORT1 is associated with angiographic burden and lesion localization in patients with premature or early clinical debut coronary atherosclerosis. Methods: This single-center, cross-sectional study analyzed a dataset collected from January to May 2023. Participants were classified as coronary atherosclerosis cases if the dataset contained an age of clinical debut of clinically significant atherosclerosis (n = 101). Controls had no recorded debut age and 0% stenosis in all assessed coronary segments (n = 27). Blood was collected in clot activator tubes; serum was stored at −40 °C until analysis. SORT1 (ng/mL) was measured using an Aviscera Bioscience ELISA. Coronary stenoses were recorded as percent diameter stenosis for left main (LM), proximal/mid/distal LAD, proximal/mid/distal LCx, and proximal/mid/distal RCA. Burden metrics included the number of segments with any stenosis (>0%), the number of obstructive segments (≥50%), the number of diseased vessels, and maximum stenosis. The prespecified primary endpoint was obstructive proximal LAD stenosis (≥50%). Nonparametric tests and Spearman correlations were used. Logistic regression evaluated the association between log2-transformed SORT1 and proximal LAD obstruction, adjusted for age, sex, LDL-C, statin use, and smoking/diabetes/hypertension durations. Results: SORT1 was higher in cases than controls (8.60 [2.60–17.10] vs. 2.30 [1.25–10.65] ng/mL; p = 0.0058). Within cases, SORT1 did not correlate with global angiographic burden (any-stenosis segments: ρ = −0.066, p = 0.513; obstructive segments: ρ = −0.060, p = 0.552; diseased vessels: ρ = −0.045, p = 0.652; maximum stenosis: ρ = −0.084, p = 0.403). Obstructive proximal LAD stenosis occurred in 44/101 (43.6%) and was associated with higher SORT1 (12.25 [4.18–17.45] vs. 4.10 [2.20–11.60] ng/mL; p = 0.0093). Each doubling of SORT1 was independently associated with proximal LAD obstruction (adjusted OR 1.48, 95% CI 1.12–1.95; p = 0.005). Conclusions: In this cross-sectional cohort, circulating SORT1 was associated with obstructive proximal LAD stenosis but not with global angiographic burden metrics. These findings are hypothesis-generating and warrant validation in independent cohorts with standardized preanalytics and prospective designs to assess temporal relationships and clinical utility.